Emergent BioSolutions Q2 2024 Adj. EPS $(2.32) Misses $(0.94) Estimate, Sales $254.700M Beat $190.000M Estimate
Portfolio Pulse from Benzinga Newsdesk
Emergent BioSolutions (NYSE:EBS) reported a Q2 2024 adjusted EPS of $(2.32), significantly missing the analyst estimate of $(0.94). However, the company reported sales of $254.7 million, beating the estimate of $190 million.
August 06, 2024 | 9:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Emergent BioSolutions reported a Q2 2024 adjusted EPS of $(2.32), missing the analyst estimate of $(0.94) by a significant margin. However, the company reported sales of $254.7 million, beating the estimate of $190 million.
The significant miss on EPS is likely to negatively impact investor sentiment and the stock price in the short term. However, the beat on sales may provide some support, but the overall impact is expected to be negative.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100